Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-acting Versus Short-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Patients: A Multicenter Phase 3 Randomized Controlled Study

NCT04101760 is registered in ClinicalTrials.gov with Lei Li as lead sponsor.

NCT NCT04101760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04101760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-acting Versus Short-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Patients: A Multicenter Phase 3 Randomized Controlled Study
Lead sponsor
Lei Li
Phase
Phase 3
Overall status
Unknown status
Start date
October 1, 2019
Completion date
October 1, 2020
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced neutropenia, colony stimulating factors adverse reaction, cost-effectiveness analysis, epithelial ovarian cancer, febrile neutropenia, drug-induced, granulocyte colony stimulating factor, overall survival, progression-free survival, quality of life